Prevalence of hepatitis B virus and hepatitis C virus infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis.

Sen Wang,Yuxin Chen,Xuejing Xu,Han Shen,Wei Hu,Junhao Chen

doi:10.18632/oncotarget.22261

Sen Wang, Yuxin Chen + Show 4 more

Open Access

https://doi.org/10.18632/oncotarget.22261

Copy DOI

Journal: Oncotarget	Publication Date: Nov 1, 2017
Citations: 15	License type: cc-by

Affiliation: Nanjing Drum Tower Hospital

Abstract

We attempted to explore the prevalence of HBV and HCV infections in patients with systemic lupus erythematous (SLE) via a systematic review. Articles published before June 2017 and, related to prevalence rates for HBV and HCV infection in SLE patient were identified in PubMed, Embase, CNKI, and Wanfang databases. Based on these searches 22 studies were selected for further analysis. The OR of HBsAg positive rate in SLE patients compared with control population was 0.28, with significant heterogeneity identified among the studies (I2 = 92%, P < 0.00001). Following exclusion of one study, the adjusted OR of HBsAg in patients with SLE was 0.24, and no significant heterogeneity was observed (I2 = 32%, P = 0.15). The adjusted OR of HBcAb positive rate in SLE patients compared with control population was 0.40, with no significant heterogeneity between studies (I2 = 0%, P = 0.56). The risk of having HCV infection by SLE patients was higher compared with the control subjects (OR = 2.91). In conclusion, this meta-analysis suggested that SLE might exert a role of protection against HBV but not for HCV infection. Further epidemiological and experimental studies are necessary to explore the role and mechanisms by which SLE affects HBV/HCV infections.

Highlights

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the two most common hepatotropic viruses responsible for majority of acute and chronic hepatitis worldwide [1]
Articles published before June 2017 and, related to prevalence rates for HBV and HCV infection in systemic lupus erythematous (SLE) patient were identified in PubMed, Embase, China National Knowledge Infrastructure (CNKI), and Wanfang databases
The odds ratio was (OR) of HBsAg positive rate in SLE patients compared with control population was 0.28, with significant heterogeneity identified among the studies (I2 = 92%, P < 0.00001)

Summary

Introduction

Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the two most common hepatotropic viruses responsible for majority of acute and chronic hepatitis worldwide [1]. Over 350 million individuals chronically infected with HBV are at high risk of developing liver cirrhosis and hepatocellular carcinoma (HCC) [2]. HBV is a small hepatotropic DNA virus. The prevalence of HBV infection varies markedly throughout the world. 45% of HBV-infected individuals live in highly endemic areas, which include China, Southeast Asia, sub-Saharan Africa and the Amazon Basin [4, 5]. Chronic infection with HCV is another major risk factor for the development of HCC worldwide. Unlike HBV, HCV is a positive-sense singlestranded RNA virus of the family Flaviviridae [6]. The highest prevalence of HCV has been reported in Africa and the Middle East, with a lower prevalence in the Americas, Australia and Northern and Western Europe [7]

Methods

Results

Conclusion